These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 32357427)
1. Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer. Gadot M; Davidson T; Aharon M; Atenafu EG; Malki A; Levartovsky M; Saad A; Domachevsky L; Berger R; Leibowitz R Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32357427 [TBL] [Abstract][Full Text] [Related]
2. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer. Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954 [TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients. Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962 [TBL] [Abstract][Full Text] [Related]
4. Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature. Stangl-Kremser J; Ricaurte-Fajardo A; Subramanian K; Osborne JR; Sun M; Tagawa ST; Bander NH Prostate; 2023 Jul; 83(10):901-911. PubMed ID: 36960580 [TBL] [Abstract][Full Text] [Related]
5. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746 [TBL] [Abstract][Full Text] [Related]
6. Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Rahbar K; Schmidt M; Heinzel A; Eppard E; Bode A; Yordanova A; Claesener M; Ahmadzadehfar H J Nucl Med; 2016 Sep; 57(9):1334-8. PubMed ID: 27056618 [TBL] [Abstract][Full Text] [Related]
7. Dosimetry of Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192 [No Abstract] [Full Text] [Related]
9. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis. Kim YJ; Kim YI Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428 [TBL] [Abstract][Full Text] [Related]
10. Results of a Prospective Phase 2 Pilot Trial of Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003 [TBL] [Abstract][Full Text] [Related]
11. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of the 177Lu-PSMA-617 therapy in the treatment of metastatic castration-resistant prostate cancer: A meta-analysis]. Zhang H; Xin P; Zhang YX Zhonghua Nan Ke Xue; 2021 Jan; 27(1):63-69. PubMed ID: 34914283 [TBL] [Abstract][Full Text] [Related]
14. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946 [TBL] [Abstract][Full Text] [Related]
15. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617. Kratochwil C; Giesel FL; Stefanova M; Benešová M; Bronzel M; Afshar-Oromieh A; Mier W; Eder M; Kopka K; Haberkorn U J Nucl Med; 2016 Aug; 57(8):1170-6. PubMed ID: 26985056 [TBL] [Abstract][Full Text] [Related]
16. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285 [TBL] [Abstract][Full Text] [Related]
18. Single Center Experience with a 4-Week Kemppainen J; Kangasmäki A; Malaspina S; Pape B; Jalomäki J; Kairemo K; Kononen J; Joensuu T Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551641 [TBL] [Abstract][Full Text] [Related]
19. Influence of short-term dexamethasone on the efficacy of Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729 [TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic potential of pretreatment Assadi M; Manafi-Farid R; Jafari E; Keshavarz A; Divband G; Moradi MM; Adinehpour Z; Samimi R; Dadgar H; Jokar N; Mayer B; Prasad V Front Oncol; 2022; 12():1066926. PubMed ID: 36568244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]